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ABSTRACT We examined four cardiomyopathy-causing mutations of troponin I that appear to disturb function by altering the
distribution of thin ﬁlament states. The R193H (mouse) troponin I mutant had greater than normal actin-activated myosin-S1
ATPase activity in both the presence and absence of calcium. The rate of ATPase activity was the same as that of the wild-
type at near-saturating concentrations of the activator, N-ethylmaleimide-S1. This mutant appeared to function by stabilizing
the active state of thin ﬁlaments. Mutations D191H, R146G, and R146W had lower ATPase activities in the presence of calcium,
but higher activities in the absence of calcium. These effects were most pronounced with mutations at position 146. For all three
mutants the rates were similar to those of the wild-type at near-saturating concentrations of N-ethylmaleimide-S1. These results,
combined with previous results, show that any alteration in the normal distribution of actomyosin states is capable of producing
cardiomyopathy. The results of the D191H, R146G, and R146W mutations are most readily explained if the intermediate state of
regulated actin has a unique function. The intermediate state appears to have an ability to accelerate the rate of ATP hydrolysis
by myosin that exceeds that of the inactive state.INTRODUCTION
Congenital cardiomyopathies are among the leading causes
of sudden cardiac death and account for a large portion of
cardiac fatalities in younger patients (1). Hypertrophic
cardiomyopathy (HCM) is the most significant type of
congenital cardiomyopathy, with an incidence of one in
500; restrictive and dilated cardiomyopathies have lower
incidences. HCM is characterized by hypertrophy of the
ventricular walls, fibrosis, myofibrillar disarray, hemody-
namic dysfunction, arrhythmias, and death (2,3). More
than 200 mutations are known to cause this disease, and
the vast majority occur on sarcomeric genes. Many of the
presenting clinical and pathological changes are due to the
release of secondary messengers, but the underlying primary
mechanism is still poorly understood (4). This underlying
cause is likely to be associated with the regulation of cardiac
muscle contraction at the sarcomeric level, where the muta-
tions are present.
Cardiac muscle contraction is regulated by the troponin (I,
T, and C subunits) and tropomyosin that are bound to actin
(5). Activation is the result of binding of Ca2þ to the troponin
C (TnC) subunit of troponin or to the high-affinity binding of
myosin to actin. High-affinity myosin binding directly alters
the position of tropomyosin on actin. Calcium binding to the
single regulatory site of cardiac TnC results in a movement
of the troponin I (TnI) inhibitory segment away from the
actin filament (6–8). Subsequently, tropomyosin alters its
position on actin (9). Changes in tropomyosin allow for
transmission of the calcium-binding signal along several
Submitted July 11, 2008, and accepted for publication December 12, 2008.
*Correspondence: chalovichj@ecu.edu
Editor: Malcolm Irving.
 2009 by the Biophysical Society
0006-3495/09/03/2237/8 $2.00monomers, and are cooperatively transmitted to neighboring
tropomyosin molecules (10–12).
These structural changes are highly dependent on the
inhibitory segment of TnI along with its C-terminal exten-
sion in cardiac muscle. Both of these regions are largely
disordered and have a greater range of motion that allows
them to transition from binding to actin in the absence of
calcium, to movement away from actin with calcium binding
(13–15). Several mutations in these regions, including those
examined in the study presented here, that cause cardiac
dysfunction and disease have been identified.
The structural changes that occur in troponin and tropo-
myosin in response to calcium binding control contraction.
Mutations in the regulatory proteins of contraction normally
alter actin stimulation of myosin ATPase activity. The
ATPase rate is dependent on both the fraction of myosin
that is bound to actin and the functional state of regulated
actin. Calcium does not have a significant effect on myosin
binding to actin during ATP hydrolysis, although it does
alter the binding of myosin-ADP and rigor myosin (16).
The major function of Ca2þ may be to alter the distribution
of functional states of the actin thin filament.
Various models have been produced that relate structure
to function (16–21). Fig. 1 shows the three structural states
that have been identified. The small circles show how the
position of tropomyosin differs in the absence and presence
of calcium, and in the rigor state (9,22,23). Although the
positions of tropomyosin have been defined, the functions
of these structural states have not been determined. In
fact, we previously examined ATPase rates under the
assumption that two of the structural states were essentially
similar in function. That ability to explain function with
doi: 10.1016/j.bpj.2008.12.3909
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fined.
Actin-troponin-tropomyosin may exist in an active or inac-
tive configuration. These states are in rapid equilibrium with
each other. The active state is partially stabilized by Ca2þ
and more so by rigor-type myosin binding. The shift in equi-
librium toward more active states increases the ATPase rate
(17,21,24). We previously showed that the cardiomyopathy-
causing mutation D14 on troponin T (TnT) shifts the equilib-
rium toward a more active state (25). Furthermore, protein
kinase C (PKC) phosphorylation of TnI shifts the equilibrium
toward the inactive state (26). We hypothesize that a disrup-
tion of the normal distribution of states is a common mecha-
nism by which many of the sarcomeric cardiomyopathy
mutations cause disease. This underlying disturbance of sar-
comeric regulation resulting in cardiac muscle dysfunction
is a likely cause of the release of numerous secondarymessen-
gers, resulting in the observed pathology.
We studied four mutations on TnI that are known to cause
restrictive cardiomyopathy and HCM: D191H, R193H,
R146G, and R146W (mouse sequence) (see http://
cardiogenomics.med.harvard.edu/project-detail?project_id¼
230#data for a comprehensive list of cardiomyopathy-
causing mutations). Residue 146 is in the disordered inhibi-
tory segment of TnI, which is unresolved in the crystal
structure, and the 191 and 193 residues occur on the
C-terminal portion of TnI, which is also largely unresolved
because of its disordered nature (27). Some structural details
of these regions have been refined with the use of nuclear
magnetic resonance techniques (13–15).
We examined the effects of these mutations on the ATPase
rates in the presence and absence of calcium. For the 193
mutation, we found that the rates were elevated in both the
presence and absence of calcium, indicating stabilization of
the active state. The results for the other three mutations
were more complex, showing an increased rate versus
FIGURE 1 Possible relationships among the different known structural
states of regulated actin and functional states (inactive, intermediate, and
active). The structural diagrams shown are schematic representations of
data presented by several groups showing tropomyosin positions on actin
in the absence and presence of calcium and in the presence of bound ‘‘acti-
vating’’ cross bridges. In three-state models of regulation, each structure is
associated with a unique function. In two-state models, two of the structures
have the same function.
Biophysical Journal 96(6) 2237–2244wild-type (WT) in the absence of calcium but a decreased
rate in the presence of calcium.
We also examined the actin-activated ATPase rates of the
mutants in the presence of the activator N-ethylmaleimide-
S1 (NEM-S1). This modified S1 shifts the regulated actomy-
osin to the fully activated state in the presence of ATP, but
has a very low actin-activated ATPase rate itself. NEM-S1
produced similar ATPase rates for all the mutants and WT
in both the absence and presence of calcium. We also
showed that there is no significant alteration of troponin
binding to actin due to these mutations. This means that no
step within the fully activated pathway is altered by the
mutants; rather, the data can be readily explained by
assuming that the mutants shifted the distribution of states.
The changes in the distribution of states required for
several of the mutants are most readily explained if there
are three functional states of regulated actin in the case of
the cardiac regulatory apparatus. Furthermore, it appears
that any deviation from the normal distribution of states
can result in cardiac disease.
MATERIALS AND METHODS
Protein preparation
Actin and myosin were isolated from rabbit back muscle (28). Myosin-S1
was made by digestion of myosin with chymotrypsin (Worthington
Biochemical, Freehold, NJ) (29). Tropomyosin was isolated from bovine
cardiac tissue. Mouse cardiac troponin C and I in pET3d, and mouse cardiac
troponin T in psBET were expressed as described previously (30).
Protein concentrations were determined by absorbance measurements at
280 nm, corrected at 340 nm for light scattering. The following extinction
coefficients (30.1%) were used: actin 1.15, myosin-S1 0.75, tropomyosin
0.23, and troponin 0.37.
Measuring ATPase rates
The actin-activated ATPase rates were determined by measuring the release
of 32P from g32P-ATP (31). Measurements were taken in the absence and
presence of calcium at 25C, pH 7.0, over a period of 10–15 min. The
production of 32P remained linear with time during this interval, so the
measured velocities are initial velocities. The reaction mixture generally
contained 1 mM ATP, 3 mM MgCl2, 10 mM MOPS, 34 mM NaCl,
1 mM EGTA or 0.5 mM CaCl2, 1 mM dithiothreitol, 10 mM actin, and
0.1 mM myosin-S1. Virtually all added NEM-S1 bound to actin under these
conditions (32,33). The actin concentration was increased to the same extent
as the NEM-S1 concentration, maintaining a constant level of free actin (34).
All rates were adjusted by subtracting the contribution due to free S1 and
NEM-S1.
Determining free troponin concentration
dependencies
Plots of ATPase activity as a function of added troponin were constructed.
The free concentration was determined by assuming that at the plateau of
activity, one troponin and one tropomyosin were bound per seven actin
monomers. The amount of troponin bound at each submaximal concentra-
tion was assumed to be proportional to the fraction of the maximum effect
on ATPase activity. With this approach, the curves were transformed to
ATPase rate versus free troponin.
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Data in the figures are shown as means, with error bars showing the standard
deviation (SD). Statistical significance (p < 0.05) was determined using the
two-sample significance t-test to compare means.
RESULTS
Previous studies have shown that the D191H, R193H,
R146G, and R146W mutations of troponin I affect ATPase
activity (30,35–37). Our goal was to determine whether these
effects are due to changes in the distribution of thin filament
states (i.e., stabilization of either the active or inactive state)
or to other factors. Mutations of troponin I could weaken the
binding of troponin to actin-tropomyosin and lead to a loss of
regulation. We therefore determined the concentration
dependencies of ATPase rates on the various troponin types.
We examined the ATPase rates in the absence of calcium
with increasing concentrations of the troponin complex.
Fig. 2 shows initial velocities of ATP hydrolysis versus the
free concentration of troponin. The estimated dissociation
constants  standard error were 0.82  0.37 mM (WT),
0.96  0.14 mM (D191H), 0.70  0.22 mM (R193H), 0.97
 0.21 mM (R146G), and 0.62  0.16 mM (R146W). These
approximate values show that there were no large changes in
the binding of troponin to actin-tropomyosin due to the
mutations. Under the conditions of our experiments, the
ATPase rates were near their minimum values at 3.6 mM
troponin in all cases. We maintained a similar ratio of
actin/tropomyosin/troponin in all other experiments to
ensure that observed changes were not due to a difference
in binding.
The data in Fig. 2 also show that each mutant was less
inhibitory than the WT at saturating concentrations of
troponin (p < 0.05). Residue 146 mutations had the greatestdecreases in inhibitory function. At saturation with tropo-
nin, the rate  SD (mM ATP/s/mM S1) for the WT was
0.12  .02. The rates for the mutants were 0.17  0.04
for D191H, 0.18  0.02 for R193H, 0.20  0.04 for
R146G, and 0.23  0.04 for R146W. At lower concentra-
tions of troponin, there were no significant differences
between the rates of the WT and mutants (p > 0.05).
Fig. 3 compares the effects of mutant and WT troponin
types on ATPase rates in the presence and absence of
calcium. The rates  SD (mM ATP/s/mM S1) in calcium
were 1.91  0.11 for WT, 1.72  0.13 for D191H, 2.05 
0.06 for R193H, 0.48  0.06 for R146G, and 0.61  0.06
for R146W. The rates in the absence of calcium were 0.13
 0.02 for WT, 0.19  0.03 for D191H, 0.18  0.02 for
R193H, 0.23  0.03 for R146G, and 0.26  0.02 for
R146W. The differences between each mutant and WT
were statistically significant in the presence and absence of
calcium (p < 0.05). The R193H mutation had a small
increase in rate in both the presence and absence of calcium.
This indicates a stabilization of the active state.
The D191H mutation showed a slight decrease in ATPase
rate in the presence of calcium and a significantly increased
rate in the absence of calcium. The R146 mutations showed
more dramatic changes, with large reductions in rate in the
presence of calcium and twofold increases in the absence of
calcium compared to WT. The altered rates in these muta-
tions could not be explained by assuming stabilization of
either the inactive or active state. These results require
that either the mutants stabilize opposite states in the
absence or presence of calcium relative to WT or they stabi-
lize a single third regulatory state with an intermediate
activity. If the intermediate state were stabilized relative to
the other states, then the population of the inactive state in
EGTA would be reduced. Furthermore, the population ofFIGURE 2 TnI mutations have little effect on the
concentration of free troponin required for 50% inhibition
of actin-activated S1 ATPase activity. Actin-activated
ATPases for WT and mutants at 0.05 M ionic strength
are shown with increasing concentrations of troponin in
the absence of Ca2þ. Initial velocities (mM ATP/s/mM
S1) are shown for WT and D191H (A), R193H (B),
R146G (C) and R146W (D). All rates were corrected for
the ATPase rate of S1 in the absence of actin (0.06 mM
ATP/s/mM S1). Data are presented as mean values  SD.
Conditions: 25C, pH 7, 0.1 mM S1, 10 mM actin,
4.3 mM tropomyosin, 1 mM ATP, 10 mM MOPS, 2 mM
MgCl2, 33 mM NaCl, 1 mM dithiothreitol, and 1 mM
EGTA.Biophysical Journal 96(6) 2237–2244
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to WT.
NEM-S1 binds tightly to actin in the presence of ATP and
shifts the filament to the active state (12). By titrating with
this activator, it is possible to observe the overall ATPase
rate as the regulated filament is shifted to the fully active
state. The actin-activated ATPase activity of NEM-S1 is
very low (0.015 mM ATP/s/mM NEM-S1), and observed
rates of ATP hydrolysis can be corrected for the contribution
due to NEM-S1. With the fully active state stabilized with
NEM-S1, we were able to screen for changes in steps that
occurred during ATP hydrolysis along that pathway. If WT
and mutant values were the same at full activation, it is
unlikely that processes such as product release were affected
by the mutation.
Fig. 4 shows the effect of increasing concentrations of
NEM-S1 in the presence of calcium. Although there were
significant differences between the WT values and those of
some mutants at low NEM-S1 concentrations, the values
FIGURE 3 Rates of actin-activated ATPase measured at near-saturating
concentrations of troponin in the presence (A) and absence (B) of calcium.
The TnI C-terminal mutants show small changes in the presence of calcium
and an increased rate in the absence of calcium, whereas both mutations at
residue 146 show large reductions in rate in the presence of calcium and
increased rates in the absence of calcium. Data are presented as mean values
 SD. All conditions and corrections are similar to Fig. 2 except that
a constant and nearly saturating concentration of troponin was used and
0.5 mM CaCl2 was substituted for EGTA in A.Biophysical Journal 96(6) 2237–2244converged at high NEM-S1 concentrations. At the highest
NEM-S1 concentration used (5 mM), there was no significant
difference between any of the mutants and the WT (p >
0.05). The theoretical curves shown in Fig. 4 were drawn
assuming the same limiting velocities in all cases (6.04 mM
ATP/s/mMS1). The data are well described by the theoretical
curves. These curves also show that the mutants differed in
their sensitivity to NEM-S1 concentration. The D191H and
R193H mutations did not show a significant difference from
WT at any NEM-S1 concentration.
The effects of NEM-S1 on ATPase activities in the
absence of calcium are shown in Fig. 5. Under these condi-
tions, the residue 146 mutations had ~2-fold higher rates than
WT in the absence of NEM-S1. However, the ratio between
the rates of WT and the mutants began to converge to one as
the NEM-S1 concentration increased. The rates for all the
mutants and WT were not significantly different at the high-
est NEM-S1 concentration used (7 mM, p > 0.05). We could
not reach the limiting rate in the absence of calcium because
of the very high NEM-S1 concentrations required and the
associated large errors. Fig. 5 shows theoretical curves for
all low calcium data sets assuming the same limiting rate
as in Ca2þ. The curves represent the data well. As in Ca2þ,
the R146G and R146W mutants had a greater sensitivity to
NEM-S1.
DISCUSSION
Congenital cardiomyopathies remain an important cause of
morbidity and mortality, with over 200 mutations identified
as disease-causing mutations for HCM alone. The pathology
of hypertrophy and secondary changes, such as fibrosis and
myofibrillar disarray, are well established, and significant
progress has been made in identifying the hormones and
secondary messengers that are responsible for these changes
(3,38). Reversing these secondary changes, however,
remains a difficult problem due to the complex interactions
and localization of the various signals. The primary treat-
ment remains symptomatic; b-blockers and other drugs are
used to reduce the load on the heart as a first line of treat-
ment, and surgical myomectomies are performed in recalci-
trant cases. In many cases the medical line of management
does not significantly alter disease progression, and the
surgical treatment is extremely invasive and carries a small
mortality risk (39).
The most direct approach to treating the disease, short of
gene manipulation, is to target the primary pathology at the
level of sarcomeric regulation. Any change in the distribution
of states may result in cardiac dysfunction. Phosphorylation
also causes changes in the distribution of states (26). There-
fore, there is the potential for altering the distribution of states
toward a more normal phenotype. As we show below, the
primary event canbe a change in the distributionof actin states.
We screened four cardiomyopathy-causing mutations to
determine whether altering the distribution between actin
TnI Mutants Alter Actin Distribution 2241FIGURE 4 Actin-activated ATPase activity of S1 with
increasing concentrations of the activator NEM-S1 in the
presence of Ca2þ. WT rates (circles) are the same in all
four panels, with the regression shown as a solid line for
the WT and a dashed line for the mutant (squares). The Mi-
chaelis-Menten equation was fit to the data using a maximal
rate of 6 s1 with varying KM values (WT ¼ 5.5 mM,
D191H ¼ 6.1 mM, R193H ¼ 6.1 mM, R146G ¼ 3.4 mM,
and R146W ¼ 2.9 mM). All rates were corrected for the
ATPase rate of S1 and NEM-S1 (0.015 mM ATP/s/mM
NEM-S1). Data are presented as mean values  SD.
Conditions: 25C, pH 7, 0.1 mM S1, 10 mM free actin,
1 mM ATP, 10 mM MOPS, 3 mM MgCl2, 33 mM NaCl,
1 mM dithiothreitol, and 0.5 mM CaCl2. Actin concentra-
tion was increased by an amount equal to the NEM-S1
added to maintain the same free actin concentration.
Actin/tropomyosin/troponin ratio was 7:3:2.5.states is a common mechanism by which mutations cause
disease. These TnI mutants were the objects of prior investi-
gations that dealt with effects on calcium sensitivity and
other functional characteristics. These earlier studies also
showed that these mutants differ from WT in their ATPase
rates in EGTA and calcium (30,35–37). Our primary interest
was in determining the differences for these changes in rate.
We first determined the saturating concentrations of troponin
and tropomyosin required to achieve full inhibition. At near-
saturating concentrations of troponin, all four mutants
showed statistically higher ATPase rates than WT in the
absence of calcium. These results also show that there arenot large differences in apparent affinity between the mutants
and WT.
The changes seen with the mutations could have been due
to alterations in the rate of some process along the active
pathway (i.e., product release). By using NEM-S1, we
were able to stabilize the fully active state of the actin fila-
ments. No differences were observed in the rates of ATP
hydrolysis between the WT and mutants under these condi-
tions. Thus it is unlikely that rates of transitions between two
nucleotide bound states are affected by the mutations of TnI.
The remaining possibility is that these mutations of
troponin I alter the equilibrium among states of regulatedFIGURE 5 Actin-activated ATPase activity of S1 with
increasing concentrations of the activator NEM-S1 in the
absence of Ca2þ. WT rates (circles) are the same in all
panels, with the regression shown as a solid line for the
WT and a dashed line for the mutants (squares). The Mi-
chaelis-Menten equation was fit to the data using a maximal
rate of 6 s1 with varying KM values (WT ¼ 9.8 mM,
D191H ¼ 9.6 mM, R193H ¼ 9.3 mM, R146G ¼ 7.1 mM,
and R146W ¼ 6.7 mM). All conditions and corrections
are similar to Fig. 4 with the exception that CaCl2 was
replaced with 1 mM EGTA.Biophysical Journal 96(6) 2237–2244
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low Ca2þ levels seen with the R193H mutation can be ratio-
nalized by stabilization of the most active state of regulated
actin. A similar shift to the active state was reported with the
D14 mutation on TnT (25). Stabilization of the inactive state
was reported in the case of protein kinase C phosphorylation
of TnI (26), which reduced the ATPase rates in both the pres-
ence and absence of calcium. The D191H, R146G, and
R146W mutants shown here exhibit the property of being
more active in EGTA and less active than the WT at satu-
rating calcium. These results require that either the mutants
stabilize opposite states in the absence or presence of
calcium relative to WT (the two-state model) or they stabilize
a single third regulatory state with an intermediate activity.
The effect of the mutations on the distribution of states in
the presence and absence of calcium is shown for a two-state
model (Fig. 6 A). Calcium binds more tightly to the active
state (K4 > K1) so that the active state is stabilized by
calcium. The D191H, R146G, and R146W mutants would
need to shift the equilibrium constant K3 to the right and
K2 to the left compared to WT to explain the ATPase rates
(heavy arrows in Fig. 6 A). It is difficult to imagine structur-
ally how a mutation that stabilizes the active state at low
calcium relative to the WT can at the same time produce
a relative stabilization of the inactive state at saturating
calcium. Detailed structural studies will further clarify
whether such a mechanism is possible.
It is more likely that conformational changes due to the
mutations will cause actin filaments to favor a single struc-
ture that corresponds to a unique functional state. That is,
the intermediate structural state proposed to exist in regu-
lated actin filaments is a unique functional state. The bold
arrows in Fig. 6 B indicate possible changes in equilibrium
constants of TnI mutants that would give the observed
ATPase rates while avoiding opposing changes of a single
step. According to this scheme, the ability of the interme-
diate state to stimulate ATPase activity must be greater
than that of the inhibited state but less than that of the fully
active state. An examination of the distributions is shown
further below.
FIGURE 6 Possible effects of R146G and R146W mutations on the
distribution of actin states in the presence (Ca2þ) and absence (0) of calcium.
In WT filaments, the equilibrium favors state i0 in the absence of calcium
and a Ca2þ in the presence of calcium. (A) Two-state model with inactive
(i) and active (a) states. (B) Three-state model with inactive (i), intermediate
(x), and active (a) states. The heavy arrows show the changes in equilibrium
constants required to explain the results of the mutants.Biophysical Journal 96(6) 2237–2244It is interesting to note that the two mutations at residue
146 have similar patterns of ATPase activity. It may be the
case that the significant change is the loss of the basic argi-
nine instead of the amino acid that replaces it. It has been
shown in skeletal troponin that arginine and lysine residues
on the troponin mobile domain are important for stabilizing
the interaction with actin (13). Examining other mutations at
this site and other cardiac troponin basic amino acids may
help refine this mechanism.
In the parallel pathway model, the overall actin-tropomy-
osin-troponin stimulated myosin ATPase rate is given by the
sum of the product of the fraction of myosin bound to each
actin state and the activity of each state. Because S1-ATP
binds with a similar affinity to myosin in the calcium-free,
calcium-bound, and NEM-S1-stabilized active states (10),
this is equivalent to the sum of the product of the activity
of each state times the fraction of actin in each state. In the
original parallel pathway model of Hill et al. (24), we
assumed that there were two states as shown in Fig. 6 A.
Calcium was thought to increase the ATPase activity by
increasing the population of the active state. That is, as in
Fig. 6 A, the affinity of calcium for the active state is greater
than that for the inactive state. Therefore, calcium increases
the fraction of actin in the active state. If another state is
included in the Hill model, as in Fig. 6 B, the observed
ATPase rate would equal fi(vi) þ fx(vx) þ fa(va), where
fi, fx, and fa are the fractions of total actin in each state,
and vi, vx, and va are the activities of the respective states.
To place limits on the distributions of states, it is necessary
to define the activities of the individual states. Because the
ATPase rates at optimal concentrations of NEM-S1 are
calcium-independent, it is likely that under this condition
virtually all of the regulated actin is in the active state (10).
This result also implies that the activity of the fully active
state is calcium-independent. We made the simplifying
assumption that the activities of the other states are also
calcium-independent.
The activity of the inactive state must be between zero and
the lowest rate we have measured (0.13/s). We assumed that
the inactive state had a true rate of 0.1/s. Essentially no actin
is in the fully active state in EGTA, in accord with our data
obtained with a pyrene tropomyosin probe (40).
The key uncertain parameter is the activity of actin fila-
ments in the intermediate state, vx. Fig. 7A shows the possible
values of the fractional occupancy of the intermediate state,
fx, as a function of the assumed activity of the intermediate
state, x, in the absence of calcium for WT and the two muta-
tions at residue 146. The minimum value of vx that is consis-
tent with the data for the R146W mutation is 0.26/s. At that
limiting value, however, the equilibrium would be shifted
totally to the intermediate state, which does not seem to be
reasonable. Therefore, the value of vx is likely to be >0.26/s.
The maximum value for vx is ~0.9/s (see below), so the
activity of vx is most likely 4–15% that of the active state
under the conditions used in these assays.
TnI Mutants Alter Actin Distribution 2243FIGURE 7 Possible distributions of states for WT and R146 mutants. (A)
Occupancy of the intermediate state as a function of assumed ATPase rates
for the intermediate state (vx). At any given vx, the fractional population of
the intermediate state is higher for themutations than for theWT. The activities
of the inactive and active states are assumed to be 0.1/s and 6/s, respectively.An
ATPase rate less than0.26/swould require a fraction larger than1.0 for the inter-
mediates state in the case of R146W, limiting vx to this minimum rate.B andC
show the fraction of states in the intermediate and active states for different
assumed fractions in the inactive state in the presence of saturating calcium.
(B) Possible distributions for the minimum possible value of vx, 0.26/s, with
‘‘X’’ indicating the intermediate state and ‘‘A’’ representing the active state.
(C) The same as B but with vx¼ 0.85/s. At this point, the lowest possible frac-
tion of the inactive state for the R146G mutation in saturating calcium is 0.5.Fig. 7, B and C, show distributions for WT and R146G at
two extreme possible values of vx. The maximum possible
value for vx is limited by the overall rate for the R146G
mutant. That rate is lower than the WT value in calcium.
At values of vx>0.85/s, the major state occupied is the inac-
tive state. At this point, the three-state model would have the
same difficulty as the two-state model (Fig. 6) in that the
mutation would stabilize opposite states in the absence and
presence of calcium. This also means that if the absolute
value of fx were determined, further restrictions would be
placed on the mutant distribution; therefore, distributions
where fx (mutant) < fx (WT) were not considered.
This analysis of a small number of mutations resulted in
a fairly low range of values for the activity of the interme-
diate state. This range will change slightly once the value
of the activity of actin in the inactive state is refined. Since
the distribution of actin states in calcium is sensitive to the
activity of the intermediate (vx) state, we can only give
ranges of values at this time. Nevertheless, these constraints
are already useful for relating other observables, such as
binding kinetics or probe fluorescence changes, to functional
actin distributions. It is important to improve the estimate of
functional state distributions so that these other readily avail-
able methods can be used to confidently determine the time
course of changes in functional state distributions. Such
information may be critical to the understanding of familial
cardiac and skeletal muscle disorders.
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